Michael J. Blake, Susan M. Abdel-Rahman, Richard F. Jacobs
Feb 1, 2005
Citations
1
Influential Citations
28
Citations
Quality indicators
Journal
Clinical Pharmacology & Therapeutics
Abstract
Rifapentine (RIF) is a rifamycin antibiotic approved for the treatment of pulmonary infections caused by M. tuberculosis that has potential therapeutic advantages over existing rifamycins. This study was designed to characterize the pharmacokinetics of RIF in children.